Hemophilia patients share their experience with a new Needle-Friendly drug

NCT ID NCT06992076

Recruiting now Knowledge-focused Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen May 07, 2026 · Last updated May 12, 2026 · Updated 1 time

Summary

This study is a registry for 100 adults and adolescents with hemophilia who are already prescribed marstacimab. The main goal is to learn whether patients prefer a simple shot under the skin (subcutaneous) over the usual intravenous injections, and to measure how much the treatment affects their daily life. Researchers will also track bleeding rates and joint health over 6 months. This is an observational study, not a test of the drug itself.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Institute of haematology and Blood diseases hospital
RECRUITING

Tianjin, Tianjin Municipality, China

Contact

Contact
The First Affiliated Hospital of Xiamen University
RECRUITING

Xiamen, Fujian, China

Contact

Conditions

Explore the condition pages connected to this study.

HEMOPHILIA